ArticlemAbs
The Antibody Society's antibody validation webinar series.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Immunoelectron microscopy: a comprehensive guide from sample preparation to high-resolution imaging.Discover nano · 2025Review
- A consensus platform for antibody characterization.Nature protocols · 2025Article
- SUMO Antibody Validation.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Antibody characterization is critical to enhance reproducibility in biomedical research.eLife · 2024Review
- Structural, Biophysical, and Computational Studies of a Murine Light Chain Dimer.Molecules (Basel, Switzerland) · 2024Article
- Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry.Acta neuropathologica · 2024Article
- Article
- A Unique G-Quadruplex Aptamer: A Novel Approach for Cancer Cell Recognition, Cell Membrane Visualization, and RSV Infection Detection.International journal of molecular sciences · 2023Article
- Construction of Synthetic Antibody Phage Display Libraries.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Validation and the Determination of Antibody Bioactivity Using MILKSHAKE and Sundae Protocols.Methods in molecular biology (Clifton, N.J.) · 2023Article
- YCharOS open antibody characterisation data: Lessons learned and progress made.F1000Research · 2023Article
- Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity.NPJ Parkinson's disease · 2022Article
- Misidentified biomedical resources: Journal guidelines are not a quick fix.International journal of cancer · 2022Article
- MALDI-TOF-MS-Based Identification of Monoclonal Murine Anti-SARS-CoV-2 Antibodies within One Hour.Antibodies (Basel, Switzerland) · 2022Article
- Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.Analytical cellular pathology (Amsterdam) · 2022Article
- Antibody Validation for Estrogen Receptor Beta.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Opinion: Independent third-party entities as a model for validation of commercial antibodies.New biotechnology · 2021Article
- Optimization of protocols for pre-embedding immunogold electron microscopy of neurons in cell cultures and brains.Molecular brain · 2021Article
- Rarely Recognized Antibody Diversification in Covid-19 Evolution to Counteract Advanced SARS-CoV-2 Evasion Strategies, and Implications for Prophylactic Treatment.Frontiers in physiology · 2021Article
- BRCA1 Antibodies Matter.International journal of biological sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.